KRAS – Discover Pharma

Welcome to Discover Pharma! Today is : October 12, 2026

KRAS

Clinical & Regulatory,Pharmaceuticals and therapeutics
FDA approves daraxonrasib for second-line pancreatic cancer
The US FDA has approved Revolution Medicines’ daraxonrasib for adults [...]

August 28, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
FDA grants Fast Track designation to Erasca pancreatic cancer drug
The FDA has granted Fast Track designation to Erasca’s investigational [...]

August 24, 2026
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development
Erasca reports encouraging Phase 1 data for ERAS-0015 and outlines Phase 3 cancer trials
Erasca has reported updated preliminary Phase 1 data for its [...]

July 14, 2026
Digital & Data,Therapeutic Areas
Insilico nominates pan-KRAS candidate ISM6166 after tumour regression in preclinical studies
Insilico Medicine has nominated ISM6166 as a preclinical candidate, positioning [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK